February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

Number 4: Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its ...

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...